Our exclusive partners
Bard Peripheral Vascular, Inc.
Bard Peripheral Vascular, Inc. is a NASDAQ listed company (“BCR”) headquartered in Tempe, Arizona, and owned by Becton Dickinson (NASDAQ: “BDX”).
It is a global leader in the development, manufacturing and marketing of innovative, life-improving and medical technologies.
Its TRUE® Flow Valvuloplasty Perfusion and TRUE® DILATATION Balloon Valvuloplasty Catheters were designed to provide precise, reliable and controlled dilatations during TAVI and BAV procedures.
The TRUE® FLOW Valvuloplasty Perfusion Catheter uses a unique eight-chamber inflation system to allow continuous cardiac blood flow through the completely inflated balloon.
The balloon was designed to provide low hemodynamic resistance; it is the only balloon providing continuous cardiac blood flow independent of the heart’s rhythmic state.
With its fiber-based shell the TRUE® FLOW balloon is rupture resistant, stays true to size and exhibits less than 1% stretch between nominal and rated burst pressure.
TRUE® DILATATION Balloon
The TRUE® DILATATION Balloon was specifically designed for BAV and TAVI procedures and supports precise, controlled and reliable dilatations.
It is fabricated from KEVLA (mesh-like material) and carbon-coated which makes the balloon highly resistant to ruptures, punctures and tears.
Fiber reinforcements precisely limit the maximum balloon diameter to the labeled size, while allowing flexible conformance to anatomical variations. The TRUE® DILATATION Balloon redefines the category, offering diameter control within a range of 1.5%.
It inflates and deflates 2 to 3 times faster than competitors’ balloons, considerably minimizing ischemia time.
These innovative closure devices are inserted via a catheter through the femoral vein into the venous vessel system and offer a safe and reliable method for the minimally invasive treatment of atrial septal defects (ASD) and patent foramen ovale (PFO).
Ultrasept devices are inserted via a catheter in an approximately 30-minute-long procedure by an interventional cardiologist; they can all be deployed without the need for open-heart surgery. This means that the majority of patients who are admitted in the morning may already return home the next day and do not have to go through the lengthy recovery process frequently following open-heart surgery.
The Ultrasept occluder was developed for the catheter-controlled transvenous closure of patent foramen ovale (PFO).
The occluder consisting of two articulating sails is easily deployed due to its flexible orientation and creates an ultra-low profile within the septum.
When designing the occluder, special focus was put on reducing metal and other foreign materials to a minimum. Patients with an existing nickel allergy, for example, can be treated with the Ultrasept occluder without incurring adverse allergic reactions.
Symedrix GmbH is a German company headquartered in Oberhaching, Bavaria, specializing in the development and distribution of medical guidewires for minimally invasive procedures.
INNOWI guidewires are mainly used to support and enhance TAVI procedures.
INNOWI as well as INNOWI SX are primarily defined by their special segmentation into three parts with different grades of stiffness. These exactly match the anatomical features and therefore provide ideal support for interventional cardiologists.
The wire shaft starts with a very hard segment followed by the yielding segment which lies in the aortic arch and the atraumatic very soft curvature positioned in the ventricle.
The only difference between INNOWI and INNOWI SX is the stiffness of the segment which lies in the aortic arch. Both wires are available in a small and large curvature.
Eclipse Medical Ltd.
These most modern closure devices are inserted via a catheter through the femoral vein into the venous vessel system and offer a safe and reliable method for the minimally invasive treatment for left atrial appendage (LAA).
These products can be deployed without the need for open-heart surgery. This means that the majority of patients who are admitted in the morning may already return home the next day and may skip a lengthy recovery process frequently following open-heart surgery.
The Omega LAA Occluder, is the dawn of a new era in LAA Closure. Its unique Cup and Disc design provides a secure anchor on which the Disc seals the ostium of the LAA.
The Cup is conformable, self-centering and self-articulating and provides a gentle pull force on the Disc that complety covers and seals the ostium.
The Omega is a one piece design made from a micromesh of platinum coated nitinol, which makes it both more radiopaque and echogenic than uncoated devices.
SmartCanula LLC is an innovative Swiss-based company in the process of solving the technical and practical problems of canulation. The venous smartcanula is the core of the first product line in our portfolio.
Access to the vascular system is a key issue for successful cardio-pulmonary bypass and other types of extracorporeal circulation. The venous smartcanula is a disposable, wall-less canula, for less invasive canulation in conjunction with extracorporeal circulation. Due to the venous smartcanula principle “collapsed canula insertion and expansion in situ”, superior blood flow by smaller access aperture with less trauma results can be achieved.
The venous smartcanula comes together with a mandrel, necessary for insertion. The device is single-use and delivered in sterile condition.
PulseCath BV is a Netherlands-based medical device company that develops, manufactures and markets circulatory support systems.
The company is focused on developing breakthrough technologies to support the life-sustaining pumping functions of the failing heart.
Founded in 2007, the company has developed a unique and proprietary platform technology to provide cardiologists and cardiac surgeons with a short-term circulatory support system.
The iVAC2L is a percutaneous ventricular assist device that uses a pneumatic drive system to generate pulsatile forward flow. The device is intended for use in patients with reduced left ventricular function who require mechanical circulatory support for up to 24 hours.
The device is a short-term, fully percutaneous, transfemoral 17Fr LVAD that effectively generates blood flow of up to 2 litres per minute and directly unloads the heart by actively aspirating from the left ventricle while creating a counter-pulsatile flow in the ascending aorta.
The iVAC 2L incorporates a patented 2-way rotary valve connected to a corporeal membrane pump via a 17Fr. single lumen, 100 cm long catheter. It can be used with any standard IABP console and requires no special hardware.